Aviado · Research
Longevity Daily
Sunday, October 11, 2026
Listen
Today's Brief
David Sinclair's ER-100 has cleared the FDA and entered human trials, making this the first rigorous test of whether biological aging can genuinely be reversed — not merely slowed. A sharp new analysis of 16 aging clocks across 51 trials challenges the reliability of the field's own measuring tools, while a GeroScience study of 28,000+ people shows your lifestyle choices are literally aging or protecting your eyes. Today's Aviado piece unpacks Vitamin K2's overlooked master-switch role: it controls where calcium travels in your body, and the dosing details actually matter.
10 stories1 peer-reviewed1 Aviado original
Cognitive Health & Neuroprotection
Your Eyes Reveal Your Brain's Biological Age — And Your Lifestyle Is Writing the Score
A GeroScience study of 28,657 UK Biobank participants found that people who scored higher on a 19-point Brain Care Score — covering physical, lifestyle, and social-emotional habits — had measurably thicker neuroretinal layers and a biologically younger retina. Since the retina is a direct extension of the central nervous system, these findings mean your everyday choices are literally visible in the structure of your eyes. Metabolic pathways involving lipid profiles and branched-chain amino acids appear to mediate the link, pointing toward specific biomarkers worth tracking.
Read more →Supplements & Compounds
Vitamin K2 Is a Master Switch for Calcium — Here's the Optimal Dose to Activate It
Vitamin K2 doesn't just support bone density — it acts as a molecular gatekeeper for calcium, directing it into bones while preventing it from calcifying arteries and soft tissue. The clinical impact extends to blood sugar: pooled data from trials involving 1,000+ people with type 2 diabetes found K2 supplementation reduces HbA1c by up to 1%, because activated osteocalcin functions as a metabolic hormone that boosts insulin sensitivity. For practical use, 90–180 mcg daily of MK-7 taken with a fat-containing meal consistently activates Gla proteins within 8–12 weeks.
Read the full Aviado analysis →Lactoferrin Shows Promise for Gut, Immune, and Mitochondrial Aging — With Important Caveats
A new review makes a plausible mechanistic case for lactoferrin in healthy aging, targeting the gut-immune-mitochondrial axis through its effects on iron regulation and immune modulation. The honest caveat: reviewers note the human evidence is sometimes presented more positively than the underlying data justify — a useful flag before adding it to your stack. Promising enough to watch, but not yet strong enough to act on without more rigorous human trial data.
Read more →Methionine Restriction's Longevity Benefits May Actually Be About Cysteine All Along
The life-extension effects credited to methionine-restricted diets may have a surprising reattribution: a Fight Aging! analysis argues the real driver is cysteine deficiency, since the body converts methionine into cysteine, and it's the shortage of cysteine — not methionine itself — that activates longevity-linked stress pathways. This matters if you're experimenting with amino acid restriction protocols, because the intervention mechanism you think you're targeting may not be the one actually doing the work. The distinction could reshape how precision restriction diets are designed.
Read more →Research & Papers
David Sinclair's ER-100 Is Now in Human Trials — The First Real Test of Age Reversal
Age reversal has crossed from hypothesis to FDA-cleared human experiment: ER-100, developed by Life Biosciences with Harvard's David Sinclair, is now being tested in people with the explicit goal of restoring aged cells to a more youthful biological state — not merely slowing their decline. Preclinical data were striking, with animal studies showing reversal of aging markers, restored vision, and efficacy in Alzheimer's and kidney disease models. ER-100 uses epigenetic reprogramming — essentially resetting the molecular instructions inside aging cells — and this trial is the first rigorous test of whether that approach holds in human biology. Whatever the results, they will set the agenda for the longevity field.
Read more →Scientists Ranked 16 Aging Clocks Across 51 Trials — and the Most-Cited Ones Have a Conflict-of-Interest Problem
A new analysis evaluated 16 epigenetic aging clocks across 51 human clinical trials and surfaced a troubling pattern: the clocks most commonly cited in age-reversal research were developed by the same groups whose interventions they're measuring. More striking still, five senolytic studies — when tested against the most trustworthy independent clocks — showed no consistent signal of slowing biological aging in humans. This is a second independent line of evidence, alongside clinical trial failures, that senolytics have not yet demonstrated in people what they clearly do in mice.
Read more →Statins May Trigger Liver Aging That Quietly Shrinks Your Muscles
New research suggests statins can induce cellular senescence in liver cells, which then suppresses IGF-1 signaling — a key anabolic pathway for maintaining muscle tissue. This could explain why some long-term statin users experience unexplained muscle loss beyond the more familiar direct statin myopathy mechanism. The findings are preliminary, but they raise the possibility that senolytics targeting hepatic senescence could one day protect muscle in susceptible patients — and suggest that anyone on long-term statins should monitor muscle mass alongside standard lipid panels.
Read more →Lifestyle & Nutrition
Aging Muscles Aren't Simply Declining — They're Actively Protecting Themselves
New research reveals that aging muscles deliberately swap power-generating fibers for protective ones as a key fat compound declines — a defensive adaptation, not simple deterioration. The counterintuitive finding: when mice were given an antioxidant that blocked this protective fiber switch, muscle function got worse, not better. This challenges the widespread assumption that antioxidant supplementation supports muscle aging, and suggests interfering with the body's built-in muscle protection strategy may backfire.
Read more →Microdosing GLP-1s for Longevity and Inflammation: The Evidence Simply Isn't There
Microdosing GLP-1 agonists like semaglutide for anti-aging, mood improvement, and inflammation is gaining traction in biohacker circles — but a direct review of the clinical literature makes a blunt point: no trial has demonstrated benefit at sub-therapeutic doses for any of these outcomes. The concept is borrowed wholesale from full-dose studies, and extrapolating effects downward lacks scientific grounding. If you're spending on microdosed GLP-1s hoping for longevity effects, the evidence doesn't currently justify the investment.
Read more →Industry & Policy
Brain Health Supplements Are Chasing Two Goals at Once — Immediate Focus and Long-Term Protection
The cognitive supplement market is splitting into two simultaneous demands: younger consumers want immediate nootropic effects, while older adults are optimizing for long-term neuroprotection — and manufacturers increasingly need ingredients that deliver both. The commercial challenge is real: most of the strongest clinical evidence for ingredients like bacopa and lion's mane points to long-term outcomes, but customers need to feel something working before they'll commit to a product. Formulators betting on this dual-benefit positioning are shaping where the next wave of brain health investment lands.
Read more →